7 completed, 3 terminated. 9 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 7, Terminated 2 |
| Phase 3 | 2 | Completed 1, Terminated 1 |
Follow vilobelimab: new trials by email Literature Review of vilobelimab trials Research Report on vilobelimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma Gangrenosum vilobelimab, Placebo - Pyoderma Gangrenosum | Phase 3 | Terminated | InflaRx GmbH | 54 | 2023-11-01 | 2025-11-04 |
| Non-comparative Study of IFX-1 Alone or IFX-1+Pembrolizumab in Patients With Locally Advanced or Metastatic cSCC. Vilobelimab, Vilobelimab + pembrolizumab combination therapy - SCC - Squamous Cell Carcinoma of Skin | Phase 2 | Terminated | InflaRx GmbH | 30 | 2021-03-31 | 2025-02-11 |
| Randomized, Controlled Study of IFX-1 in Patients With Severe COVID-19 Pneumonia IFX-1 + BSC, BSC, IFX-1 + SOC - Severe COVID-19 Pneumonia | Phase 2 / Phase 3 | Completed | InflaRx GmbH | 399 | 2020-03-31 | 2023-06-05 |
| Exploratory Study of IFX-1 in Patients With Pyoderma Gangrenosum vilobelimab - Pyoderma Gangrenosum | Phase 2 | Completed | InflaRx GmbH | 19 | 2019-05-16 | 2023-09-14 |
| Study of IFX-1 to Replace Steroids in Patients With Granulomatosis With Polyangiitis and Microscopic Polyangiitis. IFX-1, Placebo-IFX-1, Glucocorticoid (GC) - Granulomatosis With Polyangiitis (GPA), Microscopic Polyangiitis (MPA) | Phase 2 | Completed | InflaRx GmbH | 57 | 2019-04-03 | 2022-08-25 |
| Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in GPA and MPA IFX-1 low dose, IFX-1 high dose, Placebo - Granulomatosis With Polyangiitis (GPA), Microscopic Polyangiitis (MPA) | Phase 2 | Terminated | InflaRx GmbH | 20 | 2018-10-15 | 2022-05-26 |
| Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS) IFX-1, Placebo - Hidradenitis Suppurativa (HS) | Phase 2 | Completed | InflaRx GmbH | 179 | 2018-02-26 | 2021-04-08 |
| Studying Complement Inhibition in Patients With Moderate to Severe Hidradenitis Suppurativa IFX-1 - Hidradenitis Suppurativa | Phase 2 | Completed | InflaRx GmbH | 12 | 2016-12-01 | 2017-09-19 |
| Studying Complement Inhibition in Complex Cardiac Surgery IFX-1, Placebo - Systemic Inflammatory Response Syndrome, C.Surgical Procedure; Cardiac | Phase 2 | Completed | InflaRx GmbH | 116 | 2016-05-01 | 2017-02-15 |
| Studying Complement Inhibition in Early, Newly Developing Septic Organ Dysfunction CaCP29, Placebo - Severe Sepsis, Septic Shock | Phase 2 | Completed | InflaRx GmbH | 72 | 2014-04-01 | 2016-04-25 |
Granulomatosis with Polyangiitis (2) · Hidradenitis Suppurativa (2) · Inflammation (2) · Microscopic Polyangiitis (2) · Pyoderma Gangrenosum (2) · Systemic Inflammatory Response Syndrome (2) · Neoplasm Metastasis (1) · Pathologic Processes (1) · Sepsis (1) · Shock, Septic (1) · Skin Diseases (1) · Systemic Vasculitis (1)
InflaRx GmbH (10)
Germany (7) · France (5) · United States (5) · Belgium (4) · Canada (3) · Netherlands (3) · Poland (3) · Spain (3) · Greece (2) · Italy (2) · Russia (2) · Switzerland (2) · Australia (1) · Brazil (1) · Bulgaria (1)
Peter A. Merkel, MD, MPH (2) · A Vlaar, MD, PhD (1) · Alex GO Loayza, Prof, MD (1) · Anja Pfaff, PhD (1) · Korinna Pilz, MD, MS (1) · Michael Bauer, Prof. Dr. (1) · Othmar Zenker, CMO (1) · Prof. Dr. D. Schadendorf, MD (1) · Prof. Niels C. Riedemann, M.D., Ph.D. (1) · Torsten Doenst, Prof. Dr. (1)
PMID 34252397, PMID 33015643, PMID 33164993, PMID 34473343, PMID 35029045, PMID 36087611, PMID 37332066, PMID 38943192, PMID 41081529
2015 (1)